The decreased metastatic potential of rhabdomyosarcoma cells obtained through MET receptor downregulation and the induction of differentiation

Cell Death and Disease

Volumn 4, Issue 1, 2013, Pages

  Miekus, K ^a   Lukasiewicz, E ^a   Jarocha, D ^a   Sekula, M ^a   Drabik, G ^a   Majka, M ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

CXCR4; differentiation; MET; metastasis; rhabdomyosarcoma; tumor growth

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; SCATTER FACTOR RECEPTOR; CXCL12 PROTEIN, HUMAN; MET PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MYOD PROTEIN; PROTEIN KINASE B; SCATTER FACTOR; SMALL INTERFERING RNA; STROMAL CELL DERIVED FACTOR 1;

ARTICLE; BONE MARROW METASTASIS; CANCER GROWTH; CELL DIFFERENTIATION; CELL MIGRATION; CELL STRUCTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG ALVEOLUS CELL; METASTASIS INHIBITION; MORPHOLOGY; MUSCLE CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; RHABDOMYOSARCOMA; SARCOMA CELL; SIGNAL TRANSDUCTION; TUMOR VOLUME; ANIMAL; BONE MARROW CANCER; CELL MOTION; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; METASTASIS; MOUSE; MOUSE MUTANT; NONOBESE DIABETIC MOUSE; PATHOLOGY; PHOSPHORYLATION; RNA INTERFERENCE; SOFT TISSUE TUMOR; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; BONE MARROW NEOPLASMS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL MOVEMENT; CHEMOKINE CXCL12; DOWN-REGULATION; HEPATOCYTE GROWTH FACTOR; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MYOD PROTEIN; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MET; RECEPTORS, CXCR4; RHABDOMYOSARCOMA; RNA INTERFERENCE; RNA, SMALL INTERFERING; SOFT TISSUE NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS;

MLCS; MLOWN;

EID: 84872180560     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2012.199     Document Type: Article

References (55)

1. Arndt CA, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med 1999; 341: 342-352.
2. Parham DM, Barr FG. Skeletal muscle tumors. In: Fletcher CDM, Unni KK, Mertens F (eds). Pathology and Genetics of Tumors of Soft Tissue Sarcoma. IARC press: Lion, 2002, pp 141-154.
3. Davis RJ, D'Cruz CM, Lovell MA, Biegel JA, Barr FG. Fusion of PAX7 to FKHR by the Variant t(1;13)(p36;q14) Translocation in Alveolar Rhabdomyosarcoma. Cancer Res 1994; 54: 2869-2872. (Pubitemid 24187765)
4. Barr FG, Nauta LE, Davis RJ, Schǎfer BW, Nycum LM, Biegel JA. In vivo amplification of the PAX3-FKHR and PAX7-FKHR fusion genes in alveolar rhabdomyosarcoma. Hum Mol Genet 1996; 5: 15-21. (Pubitemid 26018269)
5. Davis RJ, Barr FG. Fusion genes resulting from alternative chromosomal translocations are overexpressed by gene-specific mechanisms in alveolar rhabdomyosarcoma. Proc Natl Acad Sci 1997; 94: 8047-8051. (Pubitemid 27343774)
6. Sorensen PH, Lynch JC, Qualman SJ, Tirabosco R, Lim JF, Maurer HM et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J Clin Oncol 2002; 20: 2672-2679. (Pubitemid 34575640)
7. Parham DM, Ellison DA. Rhabdomyosarcomas in adults and children: an update. Arch Pathol Lab Med 2006; 130: 1454-1465. (Pubitemid 44520712)
8. Ren YX, Finckenstein FG, Abdueva DA, Shahbazian V, Chung B, Weinberg KI et al. Mouse mesenchymal stem cells expressing PAX-FKHR form alveolar rhabdomyosarcomas by cooperating with secondary mutations. Cancer Res 2008; 68: 6587-6597.
9. Charytonowicz E, Cordon-Cardo C, Matushansky I, Ziman M. Alveolar rhabdomyosarcoma: is the cell of origin a mesenchymal stem cell? Cancer Lett 2009; 279: 126-136.
10. Carey KA, Segal D, Klein R, Sanigorski A, Walder K, Collier GR et al. Identification of novel genes expressed during rhabdomyosarcoma differentiation using cDNA microarrays. Pathol Int 2006; 56: 246-255.
11. Mazzone M, Comoglio PM. The Met pathway: master switch and drug target in cancer progression. ASEB J 2006; 20: 1611-1621. (Pubitemid 44943798)
12. Lesko E, Majka M. The biological role of HGF-MET axis in tumor growth and development of metastasis. Front Biosci 2008; 13: 1271-1280. (Pubitemid 351594710)
13. Weidner KM, Sachs M, Birchmeier W. The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells. J Cell Biol 1993; 121: 145-154. (Pubitemid 23097370)
14. Gentile A, Trusolino L, Comoglio PM. The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev 2008; 27: 85-94.
15. Chu SH, Feng DF, Zhang H, Chen ET, Duan ZX, Li XY. C-Met targeted RNA interference inhibits growth and metastasis of glioma U251 cells in vitro. J Neurooncol 2009; 93: 183-189.
16. Merlin S, Pietronave S, Locarno D, Valente G, Follenzi A, Prat M. Deletion of the ectodomain unleashes the transforming, invasive, and tumorigeneic potential of the MET oncogene. Cancer Sci 2009; 100: 633-638.
17. Ginsberg JP, Davis RJ, Bennicelli JL, Nauta LE, Barr FG. Up-regulation of MET but not neural cell adhesion molecule expression by the PAX3-FKHR fusion protein in alveolar rhabdomyosarcoma. Cancer Res 1998; 58: 3542-3546. (Pubitemid 28376547)
18. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met metastasis, motility and more. Nat Rev Mol Cell Biol 2003; 4: 915-925.
19. Takeuchi H, Bilchik A, Saha S, Turner R, Wiese D, Tanaka M. c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clin Cancer Res 2003; 9: 1480-1488. (Pubitemid 36418405)
20. Sun S, Wang Z. Head neck squamous cell carcinoma c-Metcells display cancer stem cell properties and are responsible for cisplatin-resistance and metastasis. Int J Cancer 2011; 15: 2337-2348.
21. Guo Y, Xie J, Rubin E, Tang YX, Lin F, Zi X et al. Frzb, a secreted Wnt antagonist, decreases growth and invasiveness of fibrosarcoma cells associated with inhibition of Met signaling. Cancer Res 2008; 68: 3350-3356.
22. Zillhardt M, Christensen JG, Lengyel E. An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis. Neoplasia 2010; 12: 1-10.
23. Zillhardt M, Park SM, Romero IL, Sawada K, Montag A, Krausz T. Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis. Clin Cancer Res 2011; 17: 4042-4051.
24. Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011; 10: 2298-2308.
25. Lukasiewicz E, Miekus K, Kijowski J, Drabik G, Wilusz M, Bobis-Wozowicz S et al. Inhibition of rhabdomyosarcoma's metastatic behavior through downregulation of MET receptor signaling. Folia Histochem Cytobiol 2009; 47: 485-489.
26. Libura J, Drukala J, Majka M, Tomescu O, Navenot JM, Kucia M et al. CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion. Blood 2002; 100: 2597-2606.
27. Jankowski K, Kucia M, Wysoczynski M, Reca R, Zhao D, Trzyna E et al. Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy. Cancer Res 2003; 63: 7926-7935. (Pubitemid 37466729)
28. Mǔ ller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-56. (Pubitemid 32225831)
29. Liang Z, Yoon Y, Votaw J, Goodman MM, Williams L, Shim H. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res 2005; 65: 967-971. (Pubitemid 40216458)
30. Thomas D, Kansara M. Epigenetic modifications in osteogenic differentiation and transformation. J Cell Biochem 2006; 98: 757-769. (Pubitemid 43993394)
31. Pálmer HG, Sánchez-Carbayo M, Ordóňez- Morán P, Larriba MJ, Cordón-Cardó C, Muňoz A. Genetic signatures of differentiation induced by 1alpha,25-dihydroxyvitamin D3 in human colon cancer cells. Cancer Res 2003; 63: 7799-7806. (Pubitemid 37466712)
32. Hansen LA, Sigman CC, Andreola F, Ross SA, Kelloff GJ, De Luca LM. Retinoids in chemoprevention and differentiation therapy. Carcinogenesis 2000; 21: 1271-1279. (Pubitemid 30455984)
33. Anastasi S, Giordano S, Sthandier O, Gambarotta G, Maione R, Comoglio P et al. A natural hepatocyte growth factor/scatter factor autocrine loop in myoblast cells and the effect of the constitutive Met kinase activation on myogenic differentiation. J Cell Biol 1997; 137: 1057-1068. (Pubitemid 27251041)
34. Taulli R, Bersani F, Foglizzo V, Linari A, Vigna E, Ladanyi M et al. The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation. J Clin Invest 2009; 119: 2366-2378.
35. Previdi S, Maroni P, Matteucci E, Broggini M, Bendinelli P, Desiderio MA. Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and beta-catenin/Wnt pathways. Eur J Cancer 2010; 46: 1679-1691.
36. Rong S, Bodescot M, Blair D, Dunn J, Nakamura T, Mizuno K et al. Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor. Mol Cell Biol 1992; 12: 5152-5158.
37. Zhang YW, Su Y, Lanning N, Gustafson M, Shinomiya N, Zhao P et al. Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor. Oncogene 2005; 24: 101-106. (Pubitemid 40143869)
38. Seidal T, Kindblom LG, Angervall L. Myoglobin, desmin and vimentin in ultrastructurally proven rhabdomyomas and rhabdomyosarcomas. An immunohistochemical study utilizing a series of monoclonal and polyclonal antibodies. Appl Pathol 1987; 5: 201-219. (Pubitemid 17144135)
39. Molenaar WM, Oosterhuis JW, Oosterhuis AM, Ramaekers FCS. Mesenchymal and muscle-specific intermediate filaments (vimentin and desmin) in relation to differentiation in childhood rhabdomyosarcomas. Hum Pathol 1985; 16: 838-843. (Pubitemid 15040818)
40. Carter RL, McCarthy KP, Machin LG, Jameson CF, Philp ER, Pinkerton CR. Expression of desmin and myoglobin in rhabdomyosarcomas and in developing skeletal muscle. Histopathology 1989; 15: 585-595. (Pubitemid 20022908)
41. Godbole P, Outram A, Wilcox DT, Duffy PG, Sebire NJ. Myogenin and desmin immunohistochemistry in the assessment of post-chemotherapy genitourinary embryonal rhabdomyosarcoma: prognostic and management implications. J Urol 2006; 176: 1751-1754. (Pubitemid 44389682)
42. Forte G, Minieri M, Cossa P, Antenucci D, Sala M, Gnocchi V et al. Hepatocyte growth factor effects on mesenchymal stem cells: proliferation, migration, and differentiation. Stem Cells 2006; 24: 23-33.
43. Previdi S, Abbadessa G, Daló F, France DS, Broggini M. Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown. Mol Cancer Ther 2012; 11: 214-223.
44. Ratajczak MZ, Majka M, Kucia M, Drukala J, Pietrzkowski Z, Peiper S et al. Expression of functional CXCR4 by muscle satellite cells and secretion of SDF-1 by muscle-derived fibroblasts is associated with the presence of both muscle progenitors in bone marrow and hematopoietic stem/progenitor cells in muscles. Stem Cells 2003; 21: 363-371. (Pubitemid 36623177)
45. Matteucci E, Ridolfi E, Maroni P, Bendinelli P, Desiderio MA. c-Src/histone deacetylase 3 interaction is crucial for hepatocyte growth factor dependent decrease of CXCR4 expression in highly invasive breast tumor cells. Mol Cancer Res 2007; 5: 833-845. (Pubitemid 47294811)
46. Diomedi-Camassei F, McDowell HP, De Ioris MA, Uccini S, Altavista P, Raschellá G et al. Clinical significance of CXC chemokine receptor-4 and c-Met in childhood rhabdomyosarcoma. Clin Cancer Res 2008; 14: 4119-4127.
47. Tarnowski M, Grymula K, Reca R, Jankowski K, Maksym R, Tarnowska J et al. Regulation of expression of stromal-derived factor-1 receptors: CXCR4 and CXCR7 in human rhabdomyosarcomas. Mol Cancer Res 2010; 8: 1-14.
48. Rao PK, Missiaglia E, Shields L, Hyde G, Yuan B, Shepherd CJ et al. Distinct roles for miR- 1 and miR-133a in the proliferation and differentiation of rhabdomyosarcoma cells. FASEB J 2010; 24: 3427-3437.
49. Merlino G, Helman LJ. Rhabdomyosarcoma - working out the pathways. Oncogene 1999; 18: 5340-5348. (Pubitemid 29462370)
50. Berthou S, Aebersold DM, Schmidt LS, Stroka D, Heigl C, Streit B et al. The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene 2004; 23: 5387-5393. (Pubitemid 39005814)
51. Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005; 65: 1479-1488. (Pubitemid 40270177)
52. Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res 2009; 69: 3021-3031.
53. Aguanno S, Bouché M, Adamo S, Molinaro M. 12-O- tetradecanoylphorbol-13-Acetateinduced differentiation of a human rhabdomyosarcoma cell line. Cancer Res 1990; 50: 3377-3382. (Pubitemid 20190146)
54. Pollock L, Rampling D, Greenwald SE, Malone M. Desmin expression in rhabdomyosarcoma: influence of the desmin clone and immunohistochemical method. J Clin Pathol 1995; 48: 535-538.
55. Fujita Y, Terashima M, Hoshino Y, Ohtani S, Kashimura S, Kanzaki N. Detection of cancer cells disseminated in bone marrow using real-time quantitative RT-PCR of CEA, CK19, and CK20 mRNA in patients with gastric cancer. Gastric Cancer 2006; 9: 308-314. (Pubitemid 44846555)